Closely-held Zucara Therapeutics received an additional $2-million in funding from JDRF (Juvenile Diabetes Research Foundation) to support Zucara’s planned Phase 2a study of the effect of its ZT-01 on nocturnal hypoglycemia events in Type 1 diabetes mellitus.
Zucara expects to begin patient dosing in the third quarter of 2023. JDRF has been a long-time partner of Zucara, supporting the development of ZT-01 from early discovery studies to the planned Phase 2 study.
The latest funding “underscores JDRF’s prioritization of advancing adjunctive therapies to insulin, reflecting a continuing unmet need for T1D patients,” Richard Liggins, Ph.D. and CSO of Zucara, said in a statement.
“We are hopeful that the ZONE study will demonstrate that ZT-01 can prevent potentially dangerous and disruptive low blood glucose levels overnight, and lead to the first therapeutic to treat this unintended consequence of insulin therapy,” he added.
